Skip to main content

Blue Cross Issues Warnings to Doctors Prescribing Drugs with Suicide Links. Will Insurance Companies Continue to Deny Death Protections for Suicide Victims?

Written by Sheila Matthews on . Posted in Lawmaking, MedWatch.

Patricia Weathers
President
www.ablechild.org
(845) 677-8115

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

 News that Blue Cross Insurance are warning physicians to exercise care and caution when prescribing antidepressants comes as no surprise in lieu of the recent antidepressant crisis that has plagued America for so long now and has recently come to a swift and direct result. Scrambling for damage control is a normal response under the circumstances by insurance companies nationwide. Blue Cross simply follows suit. Their actions should be viewed cautiously and with enough skepticism from those many Americans left victimized and harmed by antidepressant use. Many want to believe that insurance companies are operating in the best interest and safety of the patient. Others more attune to reality remain skeptical. What truly motivates insurance companies to take this initiative in warning doctors to be careful?

The bottom line is that the FDA has issued Black Box Warnings on all highly marketable Antidepressants after conducting a long investigation. Even with insurmountable evidence to establish their link to suicide this investigation dragged on. In a twisted and at times almost unbelievable fashion, Congress themselves had to step in to demand that the FDA disclose its data regarding certain drugs. Frustrating, and at times even ludicrous, this investigation revealed not only a clear definitive link to suicide by these drugs, but the FDA’s and drug industries desperate attempts to hide, cover-up, conceal, distort (call it what you may) clinical trial data.

In light of all these facts, it is little wonder that insurance companies are gearing up to minimize loss. Their logic in warning doctors to err on the side of caution when prescribing antidepressants is used in an attempt to save them billions in potential lawsuits.

Take for example, in the past, if a member of your family committed suicide and was taking an antidepressant or withdrawing from an antidepressant, your legal recourse, and protections under insurance is difficult at best and more often than not, nonexistent. Now up the stakes, by throwing the fact that these drugs have black box warnings on them, clearly spelling out their potential for harm. Insurance companies are between a rock and a hard place, under the gun to justify not paying claims to potential victims of the antidepressant suicide fallout.

An industry that has previously been in the driver’s seat, one that ultimately has had the final say in denying suicide victims claims, no longer has an unobstructed path to tread down. It treads today on shaky ground; no longer sure that denying death claims due to suicide, when antidepressants are involved, is in its best interest.

Accountability measures need to be enacted that would ensure that the families of victims of this antidepressant suicide crisis receive immediate protection and justice in the form of financial compensation.

Several flaws in a questionable system stress the importance of accountability here where it has been previously lacking. They are as follows:

  • Proper and full informed consent needs to be provided to the patient in writing prior to any psychiatric “treatment”. This entails revealing to the potential patient the risk of suicide when prescribing an antidepressant.
  • Toxicity testing on suicide victims is not mandated and needs to be required. Victim’s families are not provided with the information on the importance of toxicity screening and are not given the actual procedure on how to request testing at the time of death.
  • Suicides have been and are still routinely blamed on a person’s mental state or a person’s psychiatric diagnosis, rather than on the psychiatric “treatment” that the person had received prior to his death. This occurs routinely without scientific backing or verification of it being a fact. In this way, drug harm, is often overlooked or disregarded.
  • Overall, s uicides are rarely investigated on a national level. This prevents critical information from being gathered and used to factor into determining possible links or causes of suicide. Statistics need to be obtained.
  • Under “Right to Treatment”, insurance companies have been required to cover dangerous and risky psychiatric “treatment” even when the diagnosis itself does not withstand evidence-based criteria. Simply put, a person is diagnosed with a psychiatric disorder based on lists of subjective behaviors rather than on confirming, objective blood tests or brain scans.

The overall picture is one that shows the drug industry, and the psychiatric Industry conveniently not being held accountable. Both groups arm themselves with strong lobbying groups in Washington whose sole purpose is to grease the palms of our political representatives.

In the midst of all this confusion, insurance companies are left with half-hearted attempts at restoring order in a disordered and chaotic system.

For more information on the risks of suicide and antidepressants and the recent “Black Box Warnings” on antidepressants, please visit us at www.ablechild.org.

Ablechild Joins NAACP’s Call for Psychiatrist’s Resignation. Civil Rights Groups will not ignore “Gene Pool” comment.

Written by Sheila Matthews on . Posted in Lawmaking.

Patricia Weathers
President
www.ablechild.org
(845) 677-8115

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

 Recently, in a Texas Committee hearing on Psychotropic Drugs and Foster Care Children, a psychiatrist, Joe Burkett, testified regarding foster care children. In what proved to be one shocking and horrific moment for child advocates everywhere, he informed the committee that one of the main reasons so many foster kids need to be on psychotropic drugs is that “they are very sick, from a Bad Gene pool”.

Last week in Austin, civil rights groups and critics of the state’s welfare agency, of which included the NAACP, demanded the resignation of this psychiatrist.

Ablechild is in full support of the NAACP’s request. We wholeheartedly assert that we will continue to back groups committed to safeguarding children’s rights. We reassert the call for an immediate and swift kick out of office for this psychiatrist, who clearly, by his flippant and de-humanistic statements, is not representing children’s health and safety.

In response to Civil Rights groups call for his resignation, Joe Burkett, in the Dallas Morning News, October 27, 2004, said that he did nothing wrong and has no plans to quit. Questioned regarding his “Gene Pool” statement Burkett responded to the Dallas Morning News stating, “There are pretty strong genetic factors in mental illness. The comment…was really a comment about the fact that these children are in the foster care system because they don’t have normal parents making good decisions….” “That’s really the connection I’m making with genetics.”

Based upon Burkett’s recent statements, Ablechild as well as other civil rights advocates call upon Burkett to produce certifiable evidence of these “genetic factors” in foster care children.

Burkett is well aware, as are we, that there are No objective tests to verify with certainty a genetic component for mental illness. Unless Burkett can miraculously pull out of his hat scientific proof in the form of a blood test, x-ray, biopsy, or exact brain scan verifying such a statement, he should be held accountable for deceiving the public, and attempting to divert public attention away from his original and most damaging statement.

Just one example of the division within the psychiatric and medical community regarding how “scientific” psychiatric diagnoses truly are can be pulled from Clinical Psychiatry News, January 2000. Dr. Theodore Pearlman, a psychiatrist in Houston, speaking about the DSM-IV, the billing bible for psychiatry and what psychiatric diagnoses are based upon, stated that DSM-IV has gone too far. “There are too many diagnoses without any objective basis or biological support,” Dr. Pearlman went on to say.

This is one doctor out of many who have challenged the “genetic factor” and or elusive “chemical imbalance”, clearly recognizing their theoretical foundations demonstrating lack of proof.

Burkett’s comments highlight the failed approach psychiatry as a whole has marketed to the public encompassing both our foster care system and education system. Psychiatrists, like Burkett, should be held accountable for putting forth misleading and biased information to the public to skew perception or understanding of this topic.

“Marketing theories of “bad genes,” “chemical imbalances,” or “diseases” for diagnoses such as ADHD for one, has led to a tremendous increase in the number of children labeled mentally ill and trafficked into drug use without proper and full informed consent”, said Sheila Matthews, Vice President of Ablechild.org a grassroots parent organization dedicated to safeguarding children’s rights and ensuring that all receive full informed consent prior to any psychiatric “treatment”.

Children falsely accused of suffering from subjective mental disorders is a disturbing issue that has been taking place without question for far too many years. It is painfully obvious to so many now that the Psychiatric Industry is allowed to oversee the foster care system without any independent oversight or accountability. It has been a long time without justice for these children. They deserve more.

We need to recognize that it is the time to act and attempt to get both educational and healthy non-drug approaches over the walls to these unprotected children, instead of promoting and allowing the psychiatric gatekeepers and their tentative theories to remain at the helm.

For more information on mental health and its role in foster care abuse and for recent information on the FDA’s issuance of Black Box Warnings on Antidepressants given to children nationwide please visit our site at www.ablechild.org

Psychiatrist Blames Bad Gene Pool for Massive Drugging of Foster Care Children in Texas

Written by Sheila Matthews on . Posted in Lawmaking.

Patricia Weathers
President
www.ablechild.org
(845) 677-8115

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

Does this indicate the Resurgence of Eugenics in America?

On October 4, 2004 in a Texas Committee hearing on Psychotropic Drugs and Foster Care Children, human and children rights advocates were stunned when psychiatrist, Joe Burkett, informed the committee that one of the main reasons so many foster kids need to be on psychotropic drugs is “they are very sick, from a Bad Gene pool”. Another psychiatrist, Dr.Sargent, re-emphasized how very sick these kids are, and how these children’s brains are wired differently, requiring them to receive “expert” psychiatric care.

“This Bad Gene Pool” and “sickness” belief system is very alarming to many child right advocates who look to find effective, healthy, non-drug solutions for children in state care; children who more than likely have experienced trauma and stress within their environment and have had natural reactions to such. John Breeding, founder of Texans for Safe Education and author of “The Wildest Colts Make the Best Horses”, and “True Nature and Great Misunderstandings” testified before the committee. Dr. Breeding challenged the Bad Gene Pool theory. “That is just not true. Once we label these children, we stop thinking of strategies to help them succeed and master the coping skills needed in society.” Dr. Breeding called for a seven-step approach to reform, which would include strengthening informed consent laws, thereby increasing the likelihood that accurate information regarding the subjective nature of the diagnoses, being all too eagerly assigned to children placed in state care, is given to childcare providers. This would also ensure that state childcare providers given all the information, would be less likely to discount the overwhelming risks associated with drug “treatment”.

Texas is not the first state that has initiated hearings, investigations, and litigation regarding widespread abuse, which includes the rampant drugging of children within state foster care.

  • Massachusetts just this year launched an investigation into tracking how many of its children in state care are on psychiatric drugs. · Washington, California, Illinois, and Florida are just some of the other states that have tackled the overall systemic abuse as well.
  • Last year, Connecticut was the first state to actually ban the use of two unapproved antidepressants on children in state care.

What is quite clear from this is that children in the foster care system nationwide are clearly unprotected on a human rights level, and with current “bad gene pool/sickness” ideology being spread publicly, there is little hope that the current nationwide crisis within state foster care programs will get any better.

Two psychiatrists spouting comments regarding “bad genes” is alarming to say the least, but what is more disturbing is the unanswered question: Does this indicate that the American Psychiatric Association condones such ideology? If so, is any hope lying ahead for children remanded into state care? Or, are these children designated “human research subjects” for popular and profitable drug “treatments”? Ideology espousing concepts of “bad genes” and inferiority among humans based on characteristics bares a striking resemblance to the science of Eugenics that deals with the improvement of races and breeds, especially the human race, through the control of hereditary factors. We can recall that Hitler employed this same ideology in Nazi Germany. What many do not recall however is that it was also used in our country in the early 20th century within mental asylums when experimentations were conducted on people deemed an inferior sect of human beings.

This mindset contrasts sharply with our country’s founded principals of democracy, which espouses that all men are created equal.

Ablechild’s National Vice President, Ms. Sheila Matthews stated that, “This Bad Gene Pool” comment is very damning to the entire psychiatric industry and should send a wake up call to all America! These children are clearly vulnerable and are fair game for drug research, with no accountability whatsoever. All who care for children should be distraught at this public display of disregard for these children’s health and safety.”

For more information regarding foster care abuse, mental health and children, please visit us at www.ablechild.org

Black Box Warning on Antidepressants

Written by Sheila Matthews on . Posted in Lawmaking, MedWatch.

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

Gloria Wright
Vice President State of North Carolina

AbleChild is pleased with the FDA advisory panel’s move to place “black box warnings”, the strongest possible warnings that can be issued, on all antidepressants that have been linked to suicide ideations. The FDA’s hearings appear now to offer hope and healing. During the hearings held February 2 and September 13, frustrated and anguished parents and victims testified as to the horrible acts of violence, suicide, and suicide ideation induced by antidepressant use. According to their testimony, SSRI drugs had the causal effect of perpetrating these terrible tragic reactions on their loved ones. SSRI’s are a class of antidepressants still under investigation for causing suicidal thoughts and acts in children and adolescents. Eight of these SSRI drugs have been banned since last year in the U.K. for anyone under 18 years of age. The FDA never approved the use of these drugs for use in children. These drugs failed to meet the basic FDA requirement for effectiveness, yet were prescribed to children through a loophole called “off label”.

Though this move to place “black box” warnings is long overdue, it is necessary and a welcomed step toward improving the informed consent process. Our organization has regularly requested accountability, which must be required of both the drug companies and the psychiatric industry. There must be a documented informed consent process prior to treatment. Our organization will continue to work with the Congressional Investigation and Oversight Committee and FDA to ensure that the wording on warning labels are clear so there is no chance for misinterpretation.

Misinformation is itself a clear and present danger to the safety of our children. We need to focus closely on ensuring any write-ups regarding risks are straightforward, clear, and are not in any way additional attempts to mislead the public further on the part of drug companies or the psychiatric industry. The decision of the advisory panel to place a “black box warning” on these drugs will go a long way towards reducing the suicide rate in the United States .

Ablechild’s president and co-founder, Patricia Weathers testified before the Advisory Panel, “It broke my heart to see so many senseless deaths. To hide this important information from the public is a deadly secret we cannot afford to keep any longer. These families trusted the psychiatric and drug industries, and that trust was broken.”

AbleChild will attend the Connecticut Statewide Conference on Inclusion in New Canaan , Connecticut , on Saturday, October 2. We will offer the Connecticut Department of Education, parents, children’s advocates, as well as educators access to the latest information on the advisory panel’s recommendations and highlight the importance of “The Child Medication Safety Act” which is still stalled in committee in the Senate. For more information, please visit our website: www.ablechild.org.

FDA Talk Paper

Written by Sheila Matthews on . Posted in Lawmaking, MedWatch.

T04-31
Media Inquiries: 301-827-6242
Consumer Inquiries: 888-INFO-FDA

FDA Updates Its Review of Antidepressant Drugs in Children
Agency Details Plans to Present Data to Advisory Committees in September and Seek Advice on Appropriate Regulatory Actions

As part of its commitment to keep the American public fully informed about the status of its review of data concerning the use of antidepressants in pediatric patients, the Food and Drug Administration (FDA) is issuing this update to provide health care providers and patients with the most current information on this topic.

FDA has completed a new analysis of pediatric suicidality (suicidal thoughts and actions) data submitted to the agency and will be posting its analysis on its web site. FDA will also be posting on its web site additional summaries of pediatric efficacy studies from drugs that have been studied in depression in pediatric patients. Although specific new labeling language has yet to be developed, FDA will assure that the labels of the antidepressants used in pediatric patients reflect the most recent information obtained from these studies and analyses.

Next month, on September 13 and 14, 2004, FDA officials will be discussing this issue at a public meeting of its Psychopharmacologic Drugs and Pediatric Advisory Committees, at which time the agency will hear from the public and solicit the advice of the committees on these labeling changes and other possible regulatory actions.

Background

FDA has been closely reviewing the results of antidepressant studies in children since June 2003, after an initial report on studies with paroxetine (Paxil) appeared to suggest an increased risk of suicidal thoughts and actions in the children given Paxil, compared to those given placebo. Later reports on studies of other drugs supported the possibility of an increased risk of suicidal thoughts and actions in children taking these drugs. There were no suicides in any of the trials.

FDA has closely examined the studies of the antidepressants because of the potential public health impact of a link between the drugs and suicidality and the importance of these drugs in treating depression and other serious mental health conditions. On close examination of the initial reports of suicidality, it was unclear whether some of the identified suicidal behaviors reported in these studies represented actual suicide attempts or self-injurious behavior that was not suicide-related. FDA therefore arranged with Columbia University suicidality experts to review these reports.

Meanwhile, FDA brought the available information to its Psychopharmacologic Drugs Advisory Committee (PDAC) and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committees on February 2, 2004. The advisory committee members advised FDA that even before the Columbia analysis was complete, the labeling should draw more attention to the need to monitor patients closely when antidepressant therapy is initiated. Based on this recommendation, FDA asked manufacturers to change the labels of ten drugs to include stronger cautions and warnings about the need to monitor patients for worsening of depression and the emergence of suicidality, whether such worsening represents an adverse effect of the drug or failure of the drug to prevent such worsening. The new warning language has now been added to the labels for seven of these products. Sponsors for the other three drugs have agreed to adopt the language.

The “Columbia” Study

Because of concerns about whether the varied events identified by sponsors under the broad category of “possibly suicide-related” could all reasonably be considered to represent suicidality, FDA asked Columbia University to assemble an international panel of pediatric suicidality experts to undertake a blinded review of the reported behaviors using a rigorous classification system. The Columbia group submitted its completed review to FDA last month.

FDA has developed its analysis of the pediatric suicidality data, based on case classifications provided by Columbia University, and will be posting the analysis on its web site. While there are findings among these data suggestive of an increased risk of suicidality for some of these drugs, there remain inconsistencies in the results, both across trials for individual drugs and across drugs. Thus, an overall interpretation of these findings represents a substantial challenge.

The September FDA Advisory Committee Meeting

FDA’s next step, planned for some time, will be to update the Psychopharmacologic Drugs and the Pediatric Advisory Committees about the results of these reviews and to seek assistance from the committees in interpreting the data and in considering what additional regulatory actions may be needed to promote the safe use of these drugs.

As a public health agency, FDA must weigh the possibility of an increased risk of suicidality in young patients taking these drugs against the known risk of suicide in patients whose depression goes untreated.

FDA will be bringing the following issues and draft questions to the committees for their input:

  • Please comment on our approach to classification of the possible cases of suicidality (suicidal thinking and/or behaviors) and our analyses of the resulting data from the 23 pediatric trials involving 9 antidepressant drugs.
  • Do the suicidality data from these trials support the conclusion that any or all of these drugs increase the risk of suicidality in pediatric patients?
  • If the answer to the previous question is yes, to which of these 9 drugs does this increased risk of suicidality apply? Please discuss, for example, whether the increased risk applies to all antidepressants, only certain classes of antidepressants, or only certain antidepressants.
  • If there is a class suicidality risk, or a suicidality risk that is limited to certain drugs in this class, how should this information be reflected in the labeling of each of the products? What, if any, additional regulatory actions should the Agency take?
  • Please discuss what additional research is needed to further delineate the risks and benefits of these drugs in pediatric patients with psychiatric illness.

The meeting will be held in Bethesda, Maryland on September 13 and 14, 2004. So that all interested parties will have ample opportunity to review the information to be discussed next month, FDA will be posting information on its website at: http://www.fda.gov/cder/pediatric/Summaryreview.htm and http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1.htm.

GUEST OPINION: Universal Mental Health Screenings: A Call to Rally

Written by Able Child on . Posted in Interviews, Lawmaking.

By Penny Pullen, former state rep and President of Eagle Forum of IL.

OPINION — A recent letter-to-the-editor writer first asked how such an invasive law as Illinois’ new universal mental health screening atrocity could be passed, and then answered, essentially, that anything can pass any time if it’s characterized as being “for children.”

This may be true today, sad to say, but once upon a time, it was not. And so, I’m not so sure it is true.

Continue reading

Ablechild Petitions Connecticut Governor And Public Health Commissioner To Provide Public With FDA Warning On Antidepressants Before Treatment

Written by Sheila Matthews on . Posted in Lawmaking, MedWatch.

Patricia Weathers
President
www.ablechild.org
(845) 677-8115

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

 AbleChild has learned that last week the Connecticut Commissioner of Public Health, Dr. Galvin, submitted to Governor Rell a written opinion on Informed Consent relating to the recent FDA Antidepressant Warnings and their link to Suicide in adults and children. Ablechild requests that the office of Public Health, as well as the Governor’s office, provide this written opinion on informed consent to the public immediately, to ensure that the public is aware of the ongoing investigation and public health warnings regarding antidepressants and the implications surrounding this issue.

This year FDA warnings on Antidepressants immediately followed an FDA investigation, which was launched on a different class of antidepressants known as SSRI’s (Selective Serotonin Reuptake Inhibitors). This investigation and subsequent warnings comes after the United Kingdom banned the use of SSRI’s in 2003 for anyone under age 18, due to their propensity to cause suicidal ideations in children and adolescents. Currently the FDA has required that the drug companies re-label antidepressants with stronger warnings, requiring them to disclose their links to suicide.

This past week, on the Federal level, a Congressional Investigative Subcommittee Hearing, which was to investigate drug companies’ concealment of clinical data involving harm and negative side effects of Antidepressants, was abruptly shut down. This shut down, was a result of the Subcommittee Chairman’s (Congressman Greenwood-PA) acceptance of a job with one of the company’s under investigation. This recent news highlights the corruption within the political process, and the conflict of interest, both of which have sadly overrode our children’s health and safety.

In light of these facts, Ablechild has taken immediate action in Connecticut to increase public disclosure of the very real risks and life threatening warnings that these drugs have, in hopes of dispelling the myth that these drugs are safe and effective. Misinformation, comprising of the idea that these drugs are safe for our children, has been for many years, all too easily and eagerly, spread by the pharmaceutical industry manufacturing them, as well as a major portion of the mental health industry. Both of these industries have vested financial interests as top priority.

The State of Connecticut has a responsibility to protect public health. The public needs to have access to all warnings in order to make informed decisions regarding whether or not to use antidepressants for “treatment”, being recommended for depression and other psychiatric labels placed upon our children. These warnings need to be taken seriously, should be disclosed readily prior to “treatment”, and should not be overlooked. Informed Consent, hand in hand, with public safety, should be everybody’s top priority!

To read more on antidepressant warnings visit www.ablechild.org

Victims of Antidepressants Respond to Federal Corruption in Ongoing Investigation. Drug Companies’ Influence Suspends Hearing.

Written by Sheila Matthews on . Posted in Lawmaking, MedWatch.

Patricia Weathers
President
www.ablechild.org
(845) 677-8115

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

 A hearing scheduled for yesterday, July 20, 2004, by the House Energy & Commerce Subcommittee on Oversight and Investigations, headed by Congressman Greenwood of PA, was abruptly shut down just hours before it was to convene. This hearing, requested by victims, was scheduled to address both the withholding of clinical trial data from the public by drug companies, and the role of the FDA in the antidepressant investigation. Representatives from 7 pharmaceutical companies, their trade association, as well as, representatives from the American Medical Association, the American Academy of Pediatrics, and one top FDA official, were all scheduled to testify before the Subcommittee. Ablechild learned from the Associated Press that the hearing was suspended due to Congressman Greenwood’s announcement that he was seeking career opportunity from the pharmaceutical industry. This clearly raises ethical concerns.

Ablechild received a flood of calls from families outraged over the government’s depraved indifference to human rights, its lack of responsibility, and its blatant disregard for the public safety. Ablechild has put in an emergency request to the Senate to reopen these hearings to the public immediately, due to this Subcommittee’s inability to act in the best interest of the public. Parents contacting Ablechild know that the Subcommittee is unduly influenced and request that immediate action should be taken to uphold the integrity of this investigation.

On behalf of parents nationwide, Ablechild contacted Senator Santorum, from PA, specifically requesting that he take steps to reopen these hearings to ensure that the health and well being of our children is not, in any way, compromised. Ablechild points to the death of little Shaina Dunkle, from Pennsylvania, who at the age of 10, died from the direct result of antidepressants. Mrs. Vicky Dunkle, has repeatedly appealed to both Congressman Greenwood and Senator Santorum, asking for accountability in the death of her daughter. We have appealed to Pennsylvania, reminding them that Shaina Dunkle’s death should not be disregarded by the power plays of special interest groups influencing politicians and investigative hearings.

The government has the responsibility to protect public safety. Ablechild eagerly awaits Senator Santorum’s response.

National Association of School Psychology Down Plays Drug Deaths and Misleads Public on State Laws On National Public Radio

Written by Sheila Matthews on . Posted in Lawmaking, Violence.

Patricia Weathers
President
www.ablechild.org
(845) 677-8115

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

 In a NPR radio segment on the Here and Now show that aired yesterday, the National Association of School Psychology Spokesman, Peter Welley, told the public that Connecticut’s law that prohibits school personnel from recommending psychotropic drugs for children was rescinded. Connecticut’s legislation signed into law on June 28, 2001, has served as model legislation for other states around the country. Peter Welley, speaking on behalf of the organization for school psychologists, further indicated that there were many complaints launched against the Connecticut legislation.

Ablechild.org knew this public claim aired live was an outright falsehood. We suspected it to be an outlandish and meager attempt at best, to mislead the public by steering it away from the fact that this nation has been passing legislation in order to counter the epidemic of children being forced onto drugs via the public schools. Ablechild immediately launched its own investigation into this serious matter by placing a direct call into Republican Lenny Winkler’s office, the Sponsor of the Connecticut Law, as well as a practicing emergency room nurse. Her office confirmed our beliefs by assuring us that the law has not been rescinded, or in any way changed. Furthermore, AbleChild.org has learned from their office that the only complaints that they have received regarding this legislation, were from, not surprisingly, The National Association of School Psychologists. Questioned more in depth, Representative Winkler’s office indicated to us that there was not one parent complaint.

There could be several motivating factors, which prompted this organization to misrepresent the facts publicly. The possible loss of grant money is just one incentive for continuing today’s trend of labeling and drugging our children. Ablechild suspects that there will be many more similar attempts to misrepresent and divert public attention by organizations that have preyed off of our children for many years. These group’s financial incentives are on shaky ground, and it is not surprising that they grasp at thin air, in lieu of so many facts arising to the public nationwide regarding legislation and drug risks. It could be that the nation’s widespread anti-coercion Federal and State legislation, Great Britain’s ban last year of the use of 8 different antidepressants for children and adolescents, America’s own on-going FDA investigation and warnings on antidepressants, and the many Federal legal cases pending regarding informed consent and drug risks, all had a hand in making many groups a tad bit jumpy.

Children’s health and safety are being compromised daily and The Association of School Psychology takes no responsibility for this reality associated with their diagnoses and recommendations. This is a national mental health crisis, and confirms the fact that we need Federal protection in place for our children. To read about the current Federal Legislation called “The Child Medication Safety Act” and to help ensure a child’s right to grow up healthy and drug-free click here  Legislation.

Access Denied to Parents in Public Schools – A National Crisis on Informed Consent

Written by Sheila Matthews on . Posted in Lawmaking.

Patricia Weathers
President
www.ablechild.org
(845) 677-8115

Sheila Matthews
National Vice President
www.ablechild.org
(203) 966-8419

 May 19, 2004, a national news story ran out of Connecticut regarding a 7-year-old child that attacked a teacher, after he would not stop tapping his pencil. The school called in the police to subdue the child. The fact is, that this isn’t the first problem Stratford Elementary School has had with its teaching style and psychological services.

On February 12, 2004, Connecticut Stratford Police were called to Nichols Elementary School when a mother of an 8-year-old boy told police that the school administrators physically abused her son who had been diagnosed with the subjective label “ADHD”.

Ablechild.org contacted both the elementary school and the Stratford police department to request that information on the current federal Investigation into the use of behavioral drugs for children, be provided to both parents with children involved in the recent acts occurring at the school. Ablechild.org stressed to the police department the importance of providing this information to the parents to ensure that they were given proper informed consent. The Stratford Police department, though sympathetic to our request, referred us to the board of education, which outright refused our organization’s request. We strongly urged the board to provide information to the parents on the current federal investigation into the dangerous drug ‘treatment” for the controversial label “ADHD” to comply with full informed consent.

This raises serious questions regarding the lack of information parents are receiving about the label “ADHD”, behavioral drugs linked to bizarre behaviors, and suicide ideations in children that are currently under review on the Federal level.

On May 17, 2004 CBS 11 out of DALLAS-FORT WORTH Report By Investigator Ginger Allen and Producer/Photojournalist Dave Manoucheri revealed that, “Medicating children to control behavior has become a trend over the last decade, but now drug manufacturers and even the U.S. government are in the hot seat, questioned about a potentially deadly side-effect of what is supposed to be a life-saver.”

Informed consent is such an important part of the decision making process for all parents. This is a national crisis when 7 and 8 year olds need to be restrained by the police. It is time we look at the psychological programs at these elementary schools to ensure that proper informed consent is occurring.